Broadenbio Ltd., Co.
Beijing, Beijing Municipality
What changed
Phase I trial registered: A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
6mo agoTrial registeredJan 7, 2026Source filing (opens the source filing in a new tab)
Momentum
Momentum 66 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase I
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Peer position
1,004 pre-ticker oncology companies at Phase I
Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.
Compare seatsA ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE1 registered
Jul 23, 2024Advanced Solid Tumor · RECRUITING · sponsor: Shanghai Institute Of Biological Products · A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
ClinicalTrials.gov · NCT06512116 (opens the source filing in a new tab)
- Trial
PHASE1 registered
Oct 26, 2023Advanced Solid Tumor · ACTIVE_NOT_RECRUITING · sponsor: Broadenbio Ltd., Co. · A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
ClinicalTrials.gov · NCT06143007 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources